Allergan, Inc.

Allergan Sales, Inc.

Other

Arizona Board of Regents, a Body Corporate

Allergen Sales, Inc.

Daniel W Gil

Ken Chow

John E Donello

Michael E Garst

Todd M Heidelbaugh

Larry Allen Wheeler

Phong X Nguyen

Wenkui Ken Fang

Dario G Gomez

Santosh C Sinha

Mohammed I Dibas

Liming Wang

Evelyn G Corpuz

Mohammad I Dibas

John W Regan

Karen M Kedzie

Lauren M B Luhrs

Veena Viswanath

Yariv Donde

Wha-Bin Im

Jeremiah H Nguyen

Yanbin Liang

David Frederick Woodward

Smita S Bhat

Sandhya Rao

John R Cappiello

Edward Hsia

James A Burke

Stephen A Munk

Dale A Harcourt

Edwin U Padillo

Mingting Tian

Sheila X Zhou

Jyotirmoy Kusari

Kei Roger Aoki

David W Old

Janet A Takeuchi

Wha Bin Im

Danny Thang Dinh

Scott M Whitcup

Mitchell F Brin

Elizabeth WoldeMussie

Michael E Stern

Miguel Alcantara

Wheeler A Larry

Wayne Chen

Edward C Hsia

Lauren Mb Luhrs

The present invention relates to pharmaceutical compositions, containing 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, (S) 4-[1-(2,3-dimethylphenylpethyl]-1H-imidazole or (S) [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, their use as pharmaceuticals for the treatment of retinal diseases, for retinal neuroprotection and vision enhancement.

Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases

Methods of using the alpha-2-adrenergic receptor agonist of Formula I:  for improving vision such as in the treatment of ocular conditions such as presbyopia, poor night vision, visual glare, visual starbursts, visual halos, and some forms of myopia (e.g. night myopia) are described.

Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia

Disclosed herein are monospecific HCAb antibodies with antigen-binding specificity to ANG-2 and bispecific antibodies with antigen-binding specificities to ANG-2 and VEGF or PDGF.

Heavy chain only antibodies to ANG-2

Disclosed herein are monospecific HCAb antibodies with antigen-binding specificity to PDGF and bispecific antibodies with antigen-binding specificities to PDGF-2 and VEGF or to PDGF and ANG-2.

Heavy chain only antibodies to PDGF

The present invention relates to pharmaceutical compositions, containing 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, (S) 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole or (S) [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, their use as pharmaceuticals for the treatment of retinal diseases, for retinal neuroprotection and vision enhancement.

Disclosed herein is a method of upregulating regulatory T-cells, and treating diseases that would benefit from such upregulation, by administering an alpha-2 receptor agonist.

Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists

The present invention relates to a method for treating skin diseases and skin conditions in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline, or its individual enantiomers or the tautomers thereof, or a pharmaceutically acceptable salt thereof.

Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

The present invention provides a method of lowering intraocular pressure which comprises administering a therapeutically effective amount of a pharmaceutical composition comprising 4-bromo-5-(2-imidazolin-2-ylamino)benzimidazole, or a salt thereof to the affected eye of a patient, as a single dose, wherein the affected eye has an intraocular pressure less than the baseline intraocular pressure for at least eight (8) hours.

Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect

Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an &#x3b1;-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.

Methods of treating &#x3b1; adrenergic mediated conditions

Disclosed herein is a method comprising administering a compound to a mammal suffering from an inflammatory bowel disease for the treatment of said disease, said compound having a structure according to Formula I wherein X, Y, B, R, R, R, R, Rand n have the meanings found herein.

Treatment of inflammatory bowel disease

Disclosed herein is a method of treating disorders of the retina comprising administering to a patient in need of such treatment a compound selected from the group consisting of olanzapine, certain of its metabolites, clozapine, and n-desmethyl clozapine.

Methods for treating diseases of the retina

Disclosed herein is a pharmaceutical composition comprising (3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl)methanol and methods of using the composition to treat chronic pain.

Pharmaceutical compositions comprising (3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl)methanol

Growing community of inventors

Corona Del Mar, CA, United States of America

Daniel W Gil